Tang Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Tang Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$109M	Hold	2,259,889	–	–	5.53%	6
2025 Q4	$93.2M	Sell	2,259,889 -68,720	-3%	-$2.76M	4.6%	7
2025 Q3	$90.4M	Hold	2,328,609	–	–	3.48%	6
2025 Q2	$64.4M	Buy	2,328,609 +210,030	+10%	+$5.35M	3.26%	5
2025 Q1	$47.1M	Buy	2,118,579 +1,489,970	+237%	+$30.7M	2.6%	10
2024 Q4	$12.4M	Hold	628,609	–	–	0.82%	35
2024 Q3	$15.7M	Buy	628,609 +3,300	+0.5%	+$80.4K	1.12%	26
2024 Q2	$11.7M	Buy	625,309 +125,309	+25%	+$2.35M	1.19%	29
2024 Q1	$9.87M	Sell	500,000 -100,000	-17%	-$1.95M	1.03%	33
2023 Q4	$10.5M	Hold	600,000	–	–	0.97%	28
2023 Q3	$10.4M	Hold	600,000	–	–	1.47%	21
2023 Q2	$8.45M	Hold	600,000	–	–	1.24%	30
2023 Q1	$6.46M	Hold	600,000	–	–	0.96%	34
2022 Q4	$8.99M	Hold	600,000	–	–	1.31%	22
2022 Q3	$7.7M	Hold	600,000	–	–	0.94%	33
2022 Q2	$5.81M	Buy	600,000 +100,000	+20%	+$933K	0.88%	28
2022 Q1	$4.97M	Buy	+500,000	New	+$5.3M	0.99%	30

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Tang Capital Management's KNSA Position: Q1 2026 in Review

Tang Capital Management held its Kiniksa Pharmaceuticals (KNSA) position steady in Q1 2026 at 2,259,889 shares worth $109M. The position accounts for 5.53% of the portfolio, ranked #6.

Tang Capital Management first reported a position in KNSA in Q1 2022 and has held it in 17 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

Tang Capital Management held 2,259,889 shares of Kiniksa Pharmaceuticals worth $109M as of Q1 2026.
Tang Capital Management left its Kiniksa Pharmaceuticals share count unchanged in Q1 2026.
Kiniksa Pharmaceuticals made up 5.53% of Tang Capital Management's portfolio in Q1 2026, its #6 holding.
Tang Capital Management first reported a position in Kiniksa Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Tang Capital Management's 13F filing for Q1 2026, filed 15 May 2026.